Geoffrey Porges
Stock Analyst at SVB Leerink
(1.35)
# 3,401
Out of 4,876 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $24.19 | +131.50% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $29.64 | -32.52% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $7.95 | +1,157.86% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $521.00 | +63.15% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $52.21 | -8.06% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $277.13 | -22.06% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $182.31 | -25.95% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.39 | -3.42% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $110.67 | -32.23% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $47.85 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $11.22 | -10.87% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $5.22 | +14,267.82% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $441.30 | -60.34% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $17.21 | +388.09% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $38.58 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $6.67 | +814.54% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $126.08 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $24.19
Upside: +131.50%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $29.64
Upside: -32.52%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $7.95
Upside: +1,157.86%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $521.00
Upside: +63.15%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $52.21
Upside: -8.06%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $277.13
Upside: -22.06%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $182.31
Upside: -25.95%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.39
Upside: -3.42%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $110.67
Upside: -32.23%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $47.85
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $11.22
Upside: -10.87%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $5.22
Upside: +14,267.82%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $441.30
Upside: -60.34%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $17.21
Upside: +388.09%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $38.58
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $6.67
Upside: +814.54%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $126.08
Upside: -